Original ArticleNeoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
Under an Elsevier user license
open archive
Key words
PARP inhibitor
HER2-negative breast cancer
HRD
neoadjuvant therapy
olaparib
carboplatinum
Cited by (0)
This study is a joint study of the German Breast Group and the Arbeitsgemeinschaft Gynäkologische Onkologie Breast.
Note: This study was previously presented in parts as an oral presentation at the annual meeting of the American Society of Clinical Oncology in Chicago, IL 31 May to 4 June 2019.
- †
Shared first authorship.
© 2020 European Society for Medical Oncology. Published by Elsevier Ltd.